Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-12-09 9:33 pm Unchanged |
2024-12-05 | 13D | Lexicon Pharmaceuticals, Inc. LXRX |
Invus L.P. | 136,180,481 37.700% |
0 (Unchanged) |
Filing History |
| 2024-11-14 4:26 pm Sale |
2024-09-30 | 13G | Lexicon Pharmaceuticals, Inc. LXRX |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-24,435,632 (Position Closed) |
Filing History |
| 2024-11-12 10:32 am Purchase |
2024-11-08 | 13G | Lexicon Pharmaceuticals, Inc. LXRX |
FMR CORP | 49,867,042 13.794% |
11,179,919 (+28.90%) |
Filing History |
| 2024-07-29 5:44 pm Sale |
2024-07-25 | 13D | Lexicon Pharmaceuticals, Inc. LXRX |
Invus L.P. | 136,180,481 37.700% |
-38,918,903 (-22.23%) |
Filing History |
| 2024-07-10 10:10 am Purchase |
2024-07-09 | 13G | Lexicon Pharmaceuticals, Inc. LXRX |
FMR CORP | 38,687,123 10.702% |
33,018,985 (+582.54%) |
Filing History |
| 2024-05-14 5:05 pm Purchase |
2024-05-10 | 13D | Lexicon Pharmaceuticals, Inc. LXRX |
Invus L.P. | 175,099,384 48.400% |
57,546,100 (+48.95%) |
Filing History |
| 2024-03-13 9:20 pm Unchanged |
2024-03-11 | 13D | Lexicon Pharmaceuticals, Inc. LXRX |
Invus L.P. | 117,553,284 47.700% |
0 (Unchanged) |
Filing History |
| 2024-02-14 09:37 am Purchase |
2023-12-31 | 13G | Lexicon Pharmaceuticals, Inc. LXRX |
BIOTECHNOLOGY VALUE FUND L P | 24,435,632 9.980% |
8,286,453 (+51.31%) |
Filing History |
| 2023-06-05 5:48 pm Purchase |
2023-05-31 | 13D | Lexicon Pharmaceuticals, Inc. LXRX |
Invus L.P. | 117,553,284 48.000% |
27,775,050 (+30.94%) |
Filing History |
| 2023-02-13 6:20 pm Purchase |
2022-12-31 | 13G | Lexicon Pharmaceuticals, Inc. LXRX |
BIOTECHNOLOGY VALUE FUND L P | 16,149,179 8.600% |
1,789,179 (+12.46%) |
Filing History |
| 2022-08-09 4:31 pm Purchase |
2022-08-05 | 13D | Lexicon Pharmaceuticals, Inc. LXRX |
Invus L.P. | 89,778,234 47.600% |
2,426,070 (+2.78%) |
Filing History |
| 2022-08-01 4:16 pm Purchase |
2022-07-27 | 13D | Lexicon Pharmaceuticals, Inc. LXRX |
Invus L.P. | 87,352,164 47.600% |
16,173,800 (+22.72%) |
Filing History |
| 2022-02-11 8:33 pm Purchase |
2021-12-31 | 13G | Lexicon Pharmaceuticals, Inc. LXRX |
BIOTECHNOLOGY VALUE FUND L P | 14,360,000 9.600% |
3,397,000 (+30.99%) |
Filing History |
| 2022-02-09 09:22 am Sale |
2022-02-08 | 13G | Lexicon Pharmaceuticals, Inc. LXRX |
FMR CORP | 5,668,138 3.806% |
-2,629,962 (-31.69%) |
Filing History |
| 2021-01-21 4:57 pm Unchanged |
2021-01-11 | 13D | Lexicon Pharmaceuticals, Inc. LXRX |
Invus L.P. | 71,178,364 50.300% |
0 (Unchanged) |
Filing History |
| 2021-01-11 10:51 am Sale |
2021-01-08 | 13G | Lexicon Pharmaceuticals, Inc. LXRX |
FMR CORP | 8,298,100 5.864% |
-4,261,394 (-33.93%) |
Filing History |
| 2021-01-05 5:26 pm Unchanged |
2020-12-31 | 13D | Lexicon Pharmaceuticals, Inc. LXRX |
Invus L.P. | 71,178,364 50.300% |
0 (Unchanged) |
Filing History |
| 2020-12-21 4:37 pm Purchase |
2020-12-11 | 13G | Lexicon Pharmaceuticals, Inc. LXRX |
BIOTECHNOLOGY VALUE FUND L P | 10,963,000 7.800% |
10,963,000 (New Position) |
Filing History |
| 2020-12-16 4:40 pm Purchase |
2020-12-11 | 13D | Lexicon Pharmaceuticals, Inc. LXRX |
Invus L.P. | 71,178,364 50.300% |
10,937,500 (+18.16%) |
Filing History |